The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

November 1, 2010 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Pipeline

Anakinra injection (Kineret) is being evaluated for treating systemic-onset juvenile idiopathic arthritis (JIA).1 At the recent European League Against Rheumatism meeting, De Jager et al presented results of a small open-label study in which 11 of 13 patients enrolled achieved a 90% reduction in the American College of Rheumatology pediatric criteria (ACRPed90), which occurred within three weeks of initiating treatment with anakinra.2 At one year follow-up, all 11 children were still in remission. A more rigorous study with better controls needs to be performed to truly evaluate the effect of anakinra on systemic-onset JIA before more widespread use can be recommended.

You Might Also Like
  • Drug Updates
  • Drug Updates
  • Drug Updates
Explore This Issue
November 2010
Also By This Author
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Belimumab (Benlysta) has received a priority review from the FDA as a potential new treatment for systemic lupus erythematosus (SLE).3 The FDA is expected to make a decision on the drug on December 9, 2010, which is the Prescription Drug User Fee Act target date.4 The Biologics License Application was filed on June 9, 2010, which includes data from two phase III clinical trials involving 1,684 autoantibody positive patients with SLE. A Marketing Authorization Application (MAA) was filed with the European Medicines Agency (EMA) on June 4 for potential approval and use in European countries.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Calcitonin oral tablets are undergoing phase III clinical trials for the treatment of postmenopausal osteoporosis.5 Tarsa Therapeutics is investigating this once daily tablet to potentially add to the armamentarium of injectable and intranasal calcitonin products.

Canakinumab (Ilaris, ACZ885), administered as a one-time subcutaneous injection was shown to significantly reduce gout flares in a 16-week study.6 Canakinumab is a recombinant, human anti-human-interleukin-1β monoclonal antibody that is already FDA approved to treat cryopyrin-associated periodic syndromes in patients four years of age and older, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome.7 Further study is needed to fully evaluate the efficacy of this agent in treating gout patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The C.A.R.E.S. Alliance, a patient safety organization, was launched on September 8, 2010, to help curb the problem of misuse, abuse, and unintentional overdose associated with the use of opioid medications.

CH-4051 is an orally active, antifolate agent currently undergoing phase II clinical trials.8 It is being evaluated in rheumatoid arthritis patients who have had an inadequate response to methotrexate. Patient screening began in October.

Duloxetine (Cymbalta) was evaluated as a potential treatment for chronic musculoskeletal pain by the Anesthetic and Life Support Drugs Advisory Committee of the FDA.9 The committee voted by a slim margin to recommend use of duloxetine for this purpose. Based on three studies using different doses of duloxetine, it performed slightly better than placebo in treating chronic low back pain but not osteoarthritis pain. As for safety, hepatotoxicity may be an issue. It also appears to be associated with an increased risk of Stevens Johnson syndrome and toxic epidermal necrolysis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Approvals, Drugs, PipelineIssue: November 2010

You Might Also Like:
  • Drug Updates
  • Drug Updates
  • Drug Updates
  • Drug Updates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.